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Abstract
Background
Cystic fibrosis (CF) is a rare condition in Asians. Since 1985, only about 30
Chinese patients have been reported with molecular confirmation.
Method
Using our in-house next-generation sequencing (NGS) pipeline for childhood
bronchiectasis, we identified disease-causing CFTR mutations in CF patients in
Hong Kong. After identifying p.I1023R in multiple patients, haplotype analysis
was performed with genome-wide microarray to ascertain the likelihood of this
being a founder mutation. We also assessed the processing and gating activity
of the mutant protein by Western hybridization and patch-clamp test.
Results
Molecular diagnoses were confirmed in four patients, three of whom shared a
missense mutation: CFTR:c.3068T>G:p.I1023R. The results suggested that
p.I1023R is a founder mutation in southern Han Chinese. In addition, the pro-
cessing and gating activity of the mutant protein was assessed by gel elec-
trophoresis and a patch-clamp test. The mutant protein exhibited trafficking
defects, suggesting that the dysfunction is caused by reduced cell surface expres-
sion of the fully glycosylated proteins.
Conclusion
Together with other previously reported mutations, the specific founder mutation
presented herein suggests a unique CFTR mutation spectrum in the southern
Chinese populations, and this finding has vital implications for improving molec-
ular testing and mutation-specific treatments for Chinese patients with CF.
40 ª 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
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Introduction
Cystic fibrosis (CF) (OMIM 219700) is a common autoso-
mal recessive genetic disorder in Caucasian populations
with an incidence of approximately 1 in 2500–3500 new-
borns (Southern et al. 2007; Salvatore et al. 2011). Com-
pared with Western countries, CF is a considerably rarer
condition in Asia. For example, the incidence of CF is
approximately 1 in 350,000 in the Japanese population
(Yamashiro et al. 1997). The condition is caused by muta-
tions in the coding gene of the membrane glycoprotein,
cystic fibrosis transmembrane conductance regulator
(CFTR), which is responsible for regulating the flow of
chloride ions across the epithelial membrane. To date, the
number of documented disease-causing mutations in CFTR
(RefSeq NM_000492.3) exceeds 2000 (Cystic Fibrosis
Mutation Database 2016). However, molecular confirma-
tion of mutation has only been reported for 32 Chinese
patients from 1985 to 2016 (see Fig. 1 and Table S1). One
explanation for the relatively high incidence of CF in the
West is the founder effect of certain mutations (Castellani
et al. 2008). The most common mutation, p.Phe508del
(ΔF508), accounts for greater than two-thirds of CF alleles
worldwide, though it is not a predominant mutation in
Asian CF patients (Wong et al. 2003). Although founder
mutations have not yet been identified in the Chinese pop-
ulation, among the CFTR mutations found in the Chinese
population, the novel variant c.3068T>G:p.Ile1023Arg
(p.I1023R) was identified in a pair of siblings with CF from
Taiwan (Ho et al. 2007). Here, we describe the identifica-
tion of four additional patients with the p.I1023R variant
in southern China, and our results suggest that p.I1023R is
a Chinese-specific founder mutation that leads to traffick-
ing defects and reduced expression of functionally mature
CFTR protein.
Materials and Methods
Patient recruitment
This study was approved by the HKWC-HKU Institu-
tional Review Board. Informed consent was obtained
from patients (or parents) after clinical consultation.
Twenty-one patients diagnosed with early-onset
bronchiectasis were referred to our unit for clinical eval-
uation and a sweat test. Four patients with available
genomic DNA presented a strong clinical suspicion of
CF and were sweat-test positive (chloride ion concentra-
tion >60 mmol/L). Molecular diagnoses were performed
for all patients.
Experimental workflow
For a detailed description of the workflow, please refer to
the supplementary data (Appendix S1).
Results
Detection of disease-causing mutations in
CFTR
Four unrelated Chinese patients from Hong Kong were
positive for CFTR mutations, of whom three harbored a
p.I1023R mutation. These patients were all compound
heterozygotes with p.I1023R and one other disease-caus-
ing mutation. Through personal communication, we
identified another nonconsanguineous southern Chinese
CF patient from Malaysia with a homozygous p.I1023R
mutation confirmed by Sanger sequencing in our labora-
tory. Clinical and genetic data for the patients are sum-
marized in Table 1.
Figure 1. CFTR mutation spectrum in Chinese CF patients (findings from this study and previous studies reported in both English and Chinese
medical literatures from 1985 to 2016). Only variants observed in patients with complete molecular diagnosis were included. The upper panel
refers to CFTR mutations identified from Northern China (i.e., Beijing), while the lower panel refers to CFTR mutations identified from Southern
China (i.e., Sichuan, Taiwan and Hong Kong). The geographical origins of mutations were determined according to either the information
provided from the manuscript on patient recruitment, or the institute address of the corresponding authors. CFTR mutations from two reports
(Zielenski et al. 1995; Wagner et al. 1999) were not included as the corresponding institute was located outside China.
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p.I1023R is a CFTR founder mutation
localized in southern regions of China
We examined whether the p.I1023R mutation is a foun-
der mutation in the southern Han population. Using
genome-wide single-nucleotide polymorphism (SNP)
microarray genotypic data from four families, we identi-
fied a shared haplotype of p.I1023R encompassing 381
SNPs. The estimated physical length of the haplotype is
1,958,052 bp, which is equivalent to a genetic distance of
1.28 cM according to HapMap Phase II (GRCh37/hg19)
(Fig. 2). The genomic coordinates of the shared region
are chr7:115,513,497–117,471,549. The p.I1023R-asso-
ciated haplotype was then compared with the validated
control dataset that included 612 local southern Chinese
individuals (Yang et al. 2010), who were significantly
separated from Chinese Han in Beijing (CHB) HapMap
data. We did not find the specific haplotype in any of
the control samples. By estimation, the haplotype fre-
quency was less than 4.2 9 105 (P-value <0.05), and
the probability of five independent lineages (from four
p.I1023R-carrier families) by chance sharing the same
haplotype was 1.3 9 1022. The p.I1023R allele was
exclusively found in the East Asian population at an
extremely low frequency of 1.1 9 104 (1 in 8632 alle-
les), which suggests its rarity and specificity in East
Asians (Exome Aggregation Consortium 2015). We also
confirmed the birthplace of p.I1023R-carrier individuals,
and all of the parents were originally from southern pro-
vinces of China (Fig. S1). PCA analysis of genome-wide
SNP data (514,006 SNPs) clustered the families with 612
local southern Chinese controls (Fig. S2). These two lines
Figure 2. Haplotype analysis of families with the CFTR p.I1023R mutation. Pedigrees of the three Hong Kong Chinese (Families I, III and IV) and
the Malaysian Chinese (Family V) patients. Arrows mark the index CF patients of each family. The gray symbol represents an individual with an
unknown genotype. Open symbols with a dot represent healthy individuals who carry the p.I1023R mutation. p.I1023R is presented as genomic
coordinates [hg19]chr7:117250652, which is displayed in bold font. Patient I, patient III, and patient IV are heterozygous for the p.I1023R
mutation, whereas index patient V is homozygous for the p.I1023R mutation. The genotypes of selected informative SNPs located closest to the
CFTR gene are shown directly below the corresponding family members in the pedigrees.
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of evidence suggest that all four p.I1023R carrier families
are southern Han Chinese. Therefore, the above evidence
as well as sibling data from the first report on p.I1023R
from Taipei, which is located in the northern region of
Taiwan (Ho et al. 2007; Liu et al. 2014), indicate that
the mutation is a founder mutation confined to southern
regions of China.
Functional analysis demonstrates that
p.I1023R leads to a trafficking defect during
CFTR maturation without affecting the
gating function of the protein
To better understand the molecular defects of the
p.I1023R mutant CFTR protein, we investigated protein
Figure 3. Functional analysis of p.I1023R-
CFTR. A. Protein processing of wild-type CFTR,
p.F508del-CFTR and p.I1023R-CFTR. The same
immunoblotting images are presented. Each
lane contains 50 lg total protein. Band C (or
C) represents fully glycosylated and mature
CFTR, whereas Band B (or B) represents partial
glycosylated and immature CFTR. B. The
percentage ratio of Band C intensity is
normalized to the sum of band B and band C.
Data are the mean + SE (N = 6). The asterisk
indicates that the values between two groups
are significantly different (p < 0.001, one-way
ANOVA, Holm-Sidak method). C. Representative
10 second recordings show the activities of a
single wild-type CFTR and p.I1023R-CFTR in
the excised inside-out membrane patches at
1 mM ATP and room temperature. The dotted
lines indicate closed channels. D and E. The
single-channel current amplitude (i) and open
probability (Po) are presented. Data are the
mean + SE (N = 3).
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processing properties by resolving CFTR protein profile,
as previously described (Ostedgaard et al. 2007). In this
analysis, wild-type CFTR was characterized by the pres-
ence of fully glycosylated proteins was normally trans-
ported to the cell membrane, and presented increased
expression compared with mutated p.I1023R-CFTR
(Fig. 3A,B), for which a significant proportion of less-
glycosylated protein was found. This finding suggests that
the p.I1023R mutation may lead to a trafficking defect, with
reduced protein processing from the endoplasmic reticu-
lum to the Golgi apparatus. However, a single-channel
study of p.I1023R-CFTR using the patch-clamp method
(Chen et al. 2009) demonstrated that the single-channel
current amplitude (i) and open probability (Po) of the
CFTR chloride channel were not altered by the p.I1023R
mutation (Fig. 3C–E). Hence, the dysfunction caused by
p.I1023R appears to be largely caused by the reduced
expression of fully glycosylated and mature protein.
Discussion
CF has seldom been reported in Chinese individuals.
Here, a molecular diagnosis was performed for four local
Chinese patients. Our unit is the only center that offers
sweat testing in Hong Kong, a city located in southern
China with a population of approximately 7.3 million.
We estimated that the incidence of CF is approximately 1
in 300,000 live births in Hong Kong, which is similar to
that in Japan (Yamashiro et al. 1997).
We identified the missense mutation p.I1023R in three
of four CF patients from Hong Kong as well as in an
additional Chinese patient (homozygous) from Malaysia.
All four patients with the p.I1023R mutation exhibited
had recurrent pneumonia and bronchiectasis. Pseu-
domonas aeruginosa was isolated from all patients, and a
more diverse respiratory tract flora was noted in two
patients. Three patients had pancreatic insufficiency, and
two had meconium ileus. In the limited number of cases
presenting with the classical clinical features of CF, we
did not observe an association of p.I1023R with a unique
clinical phenotype.
The identification of multiple patients with p.I1023R
led us to hypothesize that p.I1023R is a potential foun-
der mutation in southern Han Chinese. We defined the
following criteria and examined the likelihood of our
hypothesis: (1) all patients and p.I1023R carriers share a
haplotype associated with the p.I1023R mutation;
(2) the p.I1023R-associated haplotype was shared among
affected families with a genetic distance greater than
1 cM; (3) the mutant allele was rare and specific to the
population (Fachal et al. 2012); (4) the p.I1023R-asso-
ciated haplotype was unique in the normal population;
and (5) all carriers were delineated to the same
geographic region. Our experimental data were well fit
to these criteria well, and we concluded that p.I1023R
is indeed a founder mutation in southern Han Chinese.
The additional patient from Malaysia who was homozy-
gous for p.I1023R further supported our conclusion.
Because the founder haplotype of this mutation was
well defined, the time of emergence of p.I1023R can be
estimated. Assuming all five p.I1023R lineages from four
families to be independent, all of the patients from this
study inherited the mutation from a common ancestor
approximately 15.6 generations (i.e., meiotic events)
ago.
Although p.I1023R is the most common CFTR mutation
in our cohort, it was not observed in the cohort of 20 CF
patients recently reported by investigators from Beijing
(Liu et al. 2015; Tian et al. 2016). Another Chinese-specific
mutation, p.G970D, appears to be more commonly
observed in northern Chinese with CF. We summarize our
findings along with previously reported CFTR mutations.
Interestingly, an obvious difference is observed in the spec-
trum of CFTR mutations between the northern and south-
ern regions of China (Fig. 1). Although further studies
must be performed to elucidate the complete picture of
CFTR molecular epidemiology in China, current evidence
suggests that compared with Caucasians, Chinese CF
patients have a different CFTR mutation spectrum. As
translating CF molecular tests into clinical practice, such as
through the use of a 23-variant ACMG CF panel (Watson
et al. 2004), will result in a low diagnostic yield when
applied to Chinese patients, a customized Chinese-specific
CF panel may be required to investigate the incidence of
CF in Chinese patients. This Chinese-specific CF panel is
not only relevant for Asian countries but also for other
parts of the world that present significant population of
Chinese immigrants. For example, the 2011 US Census
reported that the Chinese American population included
approximately 3.8 million individuals and accounted for
1.2% for the overall population.
Here, we illustrate that p.I1023R causes a disruption in
CFTR intracellular processing, though the conductance (i)
and channel open probability (Po) remained similar to
that of the wild-type protein. Our calculation of normal
CFTR expression (i.e., 25%) is likely an overestimate
(Moran and Zegarra-Moran 2008). We tested expression
of the mutant protein via the overexpression of foreign
plasmids in a cell line and analyzing the total protein
content from the cell extract, including the CFTR protein
trapped in the Golgi apparatus and cell membrane. How-
ever, the band intensity ratio did not reflect the actual
proportion of functional CFTR in the cell membrane
compared with wild-type CFTR. In addition, we did not
define an association between the physiological values of
p.I1023R-associated CFTR expression and a clinical
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phenotype of CF. Moreover, our data clearly indicate that
muturation of the p.I1023R-CFTR protein maturation
was inhibited.
In general, genetic mutations primarily disrupt CFTR
functions by reducing protein expression or channel
activity. We functionally characterized p.I1023R as a class
II CFTR mutation (reducing protein expression) based on
the functional properties of the gene product as originally
proposed by Tsui (1992). Similar to p.I1023R, several
other mutations, such as p.A561E, p.S1235R, and
p.N1303K, are also to class II mutations according to
their pathological mechanism (Welsh and Smith 1993;
Mendes et al. 2003). Understanding the pathological
mechanisms of each class of mutation can shed light on
the development of mutation-specific therapies. For
instance, the protein maturation process affected by
p.A561E was enhanced by lumacaftor treatment (Awatade
et al. 2014), whereas human cell lines with p.S1235R and
p.N1303K responded positively to treatment with small
molecular correctors (Rapino et al. 2015). Thus, our find-
ings can be used as the basis for future clinical trials in
drug development.
To conclude, we provide the first report of a founder
mutation, p.I1023R, in CFTR in southern Chinese indi-
viduals as well as a functional characterization of this
mutation. Because this mutation and other known muta-
tions found in Chinese patients are not currently included
in the conventional CFTR gene panel for the molecular
diagnosis of CF, we suggest a different CFTR gene panel
or mutation screening strategy for CF patients of Chinese
origin.
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